Mylan’s recently FDA-approved Advair Diskus generic to be offered at 70% cost reduction to its reference drug, and 67% less than GSK’s generic version.
The price of running a clinical trial to obtain FDA approval is a fraction of the total drug development cost – challenging traditionally held beliefs about the amount of money required to study prescription drugs, according to new research.
Strategikon Pharma has released a new cloud-based solution to help plan, source, and manage clinical programs – with the goal of eliminating paper-based processes.
Apprentice has raised $2.5m in venture funding for its augmented reality solution, Affinity, which is designed to improve productivity, audit readiness quality, and safety within pharmaceutical lab and research environments, says CEO.
As it becomes increasingly expensive to develop drugs, analysts predict that deal-making will become more important for pharmaceutical companies seeking to offset R&D costs.
Looking for a full-on partnership with Pfizer or a no-strings-attached manufacturing deal? Either way prepare for a tough screening process and don't be located too far from an airport.
Pharma firms are returning to European and North American manufacturers as quality issues and rising costs have lost India and China some of its ‘Eastern promise,’ according to industry experts.
AmerisourceBergen has announced upbeat Q1 results as contributions from Consulting Services and World Courier offsets ongoing cost issues in Drug Distribution.
Catalent has replaced all stainless steel bioreactors at its biologics facility in Middleton, Wisconsin with single-use techs citing cost and flexibility advantages.
Granules India saw API sales rocket in the fiscal first quarter due – according to the firm – to an efficiency drive and the impact of rising prices in China.
Albemarle says it will increase what it charges for generic APIs from next month, citing increasing regulatory and testing costs as the main reasons for the hike.
Unilife saw its losses increase in the second quarter of fiscal 2011 on the lack of industrialisation revenue, higher R&D spending and the cost of its move to the US.
RecipharmCobra Biologics has called for more R&D tax breaks in Europe after French Ministry of Higher Education and Research recognises it as key provider.
Tripos has announced the sale of its Discovery Informatics
Business, as an initial step towards liquidation, in light of the
current trend to low-cost Asian outsourcing.
Despite looming threats from cheap Asian competitors, European
contract research organisations (CROs) still have a fighting chance
in the global R&D outsourcing market, according to a report by
research analysts Frost & Sullivan.
Specialty chemicals group H&R Wasag witnessed tremendous growth
in the first quarter of 2006, as stable crude oil prices allowed it
to increase prices and volumes in the pharmaceutical raw materials
it sells.
UK company ComplianceControl is launching new software to
streamline the compliance control process, saving precious time and
money for pharmaceutical manufacturing companies of all sizes.
BASF has announced that it is to raise prices of its pharmaceutical
excipients in a move that represents the wider market that has seen
big cost increases for raw materials, energy and transportation
that has affected all excipient...
FMC BioPolymer said today that effective 15 October, it will
increase prices for its pharmaceutical and food brand products by 5
to 10 per cent on average, blaming increases in its own costs.
The challenging environment for companies supplying chemicals into
the pharmaceutical sector, with a relentless increase in
competition, has prompted German company Merck KGaA to start a new
service aimed at reducing the workload...
The UK Packaging and Industrial Films Association (PIFA) is warning
buyers of plastic film products to expect further price increases
as producers and converters are forced to look for recovery of
exceptional rising raw material costs....
Finnish packaging giant Huhtamaki has reported flat sales figures
in the third quarter of 2004 due to adverse currency translations
and high raw material costs.
